Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity.
CPT-11
Gastrointestinal mucositis
MC-38 cells
TLR4 antagonist
Toll-like receptor 4 (TLR4)
Tumour
Journal
Cancer chemotherapy and pharmacology
ISSN: 1432-0843
Titre abrégé: Cancer Chemother Pharmacol
Pays: Germany
ID NLM: 7806519
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
13
04
2022
accepted:
03
08
2022
pubmed:
13
8
2022
medline:
27
8
2022
entrez:
12
8
2022
Statut:
ppublish
Résumé
Gastrointestinal mucositis (GIM) is a side effect of high-dose irinotecan (CPT-11), causing debilitating symptoms that are often poorly managed. The role of TLR4 in the development of GIM has been clearly demonstrated. We, therefore, aimed to investigate the potential of the TLR4 antagonist, IAXO-102, to attenuate gastrointestinal inflammation as well as supress tumour activity in a colorectal-tumour-bearing mouse model of GIM induced by CPT-11. 24 C57BL/6 mice received a vehicle, daily i.p. IAXO-102 (3 mg/kg), i.p. CPT-11 (270 mg/kg) or a combination of CPT-11 and IAXO-102. GIM was assessed using validated toxicity markers. At 72 h, colon and tumour tissue were collected and examined for histopathological changes and RT-PCR for genes of interest; TLR4, MD-2, CD-14, MyD88, IL-6, IL-6R, CXCL2, CXCR1, and CXCR2. IAXO-102 prevented diarrhoea in mice treated with CPT-11. Tumour volume in IAXO-102-treated mice was lower compared to vehicle at 48 h (P < 0.05). There were no differences observed in colon and tumour weights between the treatment groups. Mice who received the combination treatment had improved tissue injury score (P < 0.05) in the colon but did not show any improvements in cell proliferation or apoptotic rate. Expression of all genes was similar across all treatment groups in the tumour (P > 0.05). In the colon, there was a difference in transcript expression in vehicle vs. IAXO-102 (P < 0.05) and CPT-11 vs. combination (P < 0.01) in MD-2 and IL-6R, respectively. IAXO-102 was able to attenuate symptomatic parameters of GIM induced by CPT-11 as well as reduce tissue injury in the colon. However, there was no effect on cell proliferation and apoptosis. As such, TLR4 activation plays a partial role in GIM development but further research is required to understand the specific inflammatory signals underpinning tissue-level changes.
Identifiants
pubmed: 35962138
doi: 10.1007/s00280-022-04463-x
pii: 10.1007/s00280-022-04463-x
pmc: PMC9402738
doi:
Substances chimiques
Amino Sugars
0
Antineoplastic Agents
0
Glycolipids
0
IAXO-102
0
Toll-Like Receptor 4
0
Irinotecan
7673326042
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
267-278Informations de copyright
© 2022. The Author(s).
Références
Int J Exp Pathol. 2011 Oct;92(5):357-65
pubmed: 21463374
Nat Rev Cancer. 2004 Apr;4(4):277-84
pubmed: 15057287
Curr Opin Oncol. 2007 Jul;19(4):323-7
pubmed: 17545794
Cancer Chemother Pharmacol. 2022 Feb;89(2):275-281
pubmed: 34854953
Cancer Biol Ther. 2008 Jul;7(7):1139-45
pubmed: 18535404
Toxicology. 2013 Dec 15;314(2-3):262-6
pubmed: 23831209
Pharmacol Biochem Behav. 1993 Jun;45(2):465-72
pubmed: 8327553
Radiat Oncol. 2010 Mar 16;5:22
pubmed: 20233440
J Nutr. 1996 Oct;126(10):2519-30
pubmed: 8857513
Front Cell Infect Microbiol. 2017 Oct 26;7:455
pubmed: 29124041
Arzneimittelforschung. 1985;35(5):804-8
pubmed: 4026903
PLoS One. 2012;7(10):e47510
pubmed: 23091630
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Front Immunol. 2021 May 07;12:669747
pubmed: 34025672
Atherosclerosis. 2015 Oct;242(2):563-70
pubmed: 26318106
Chemotherapy. 2007;53(5):360-9
pubmed: 17713326
Support Care Cancer. 2019 Jun;27(6):2313-2320
pubmed: 30350190
Cancer Res. 2011 Mar 1;71(5):1989-98
pubmed: 21363926
Cancer Res. 2005 Jun 15;65(12):5009-14
pubmed: 15958541
Cell Mol Immunol. 2014 Mar;11(2):150-9
pubmed: 24362470
Onco Targets Ther. 2013 Nov 05;6:1573-87
pubmed: 24235843
Microbiology (Reading). 2015 Oct;161(10):1950-1960
pubmed: 26224606
Support Care Cancer. 2016 May;24(5):2251-2258
pubmed: 26581898
Gut. 2000 Nov;47(5):632-7
pubmed: 11034578
J Immunol. 2005 May 15;174(10):6416-23
pubmed: 15879143
Cancer Chemother Pharmacol. 2021 Mar;87(3):327-336
pubmed: 33130913
Mol Cancer Ther. 2016 Jun;15(6):1376-86
pubmed: 27197307
Cancer Chemother Pharmacol. 2017 Feb;79(2):431-434
pubmed: 28011980
Br J Pharmacol. 2021 Oct;178(20):4193-4209
pubmed: 34216140
Curr Opin Support Palliat Care. 2016 Jun;10(2):157-64
pubmed: 26986508
Br J Cancer. 2013 Feb 19;108(3):479-85
pubmed: 23299535
Cancer Chemother Pharmacol. 2018 Jul;82(1):31-37
pubmed: 29845394